title: Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
abstract: Human topoisomerase I (top1) is an important target for anti-cancer drugs, which include camptothecin (CPT) and its derivatives. To elucidate top1 inhibition in vitro, we made a series of duplex DNA substrates containing a deoxyadenosine stereospecifically modified by a covalent adduct of benzo[a]pyrene (BaP) diol epoxide [Pommier, Y., et al. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 10739-10744]. The known orientation of the hydrocarbon adduct in the DNA duplex relative to the top1 cleavage site, in combination with a top1/DNA crystal structure [Redinbo, M. R., et al. (1998) Science 279, 1504-1513], was used to construct a structure-based model to explain the in vitro top1 inhibition results obtained with adducted DNA duplexes. Here we experimentally determined that the lactone form of CPT was stabilized by an irreversible top1/DNA covalent complex. We removed the BaP moiety from the DNA in the published model, and docked the lactone forms of CPT and derivatives into the top1/DNA active site cavity. The docked ligands were minimized, and interaction energy scores between the ligands and the top1/DNA complex were determined. CPT docks perpendicular to the DNA backbone, projects outward from the major groove, and makes a network of potential H-bonds with the active site DNA and top1 residues, including Arg364, Lys532, and Asn722. The results are consistent with the known structure-activity relationships of CPT and derivatives. In addition, the model proposed a novel top1/N352A "resistance" mutation for 10-OH derivatives of CPT. The in vitro biochemical characterization of the top1/N352A mutant supported the model.
authors.affiliation: Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: Gary S
authors.initials: GS
authors.lastname: Laco
authors.forename: Jack R
authors.initials: JR
authors.lastname: Collins
authors.forename: Brian T
authors.initials: BT
authors.lastname: Luke
authors.forename: Heiko
authors.initials: H
authors.lastname: Kroth
authors.forename: Jane M
authors.initials: JM
authors.lastname: Sayer
authors.forename: Donald M
authors.initials: DM
authors.lastname: Jerina
authors.forename: Yves
authors.initials: Y
authors.lastname: Pommier
mesh_terms: D001665:Binding Sites / Q000235:genetics; D001667:Binding, Competitive / Q000235:genetics; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000737:chemistry*; D004247:DNA / Q000737:chemistry; D004264:DNA Topoisomerases, Type I / Q000737:chemistry*; D004791:Enzyme Inhibitors / Q000737:chemistry*; D006801:Humans; D006860:Hydrogen Bonding; D000077146:Irinotecan; D008958:Models, Molecular; D008968:Molecular Conformation; D009692:Nucleic Acid Heteroduplexes / Q000737:chemistry; D013329:Structure-Activity Relationship; D013379:Substrate Specificity / Q000235:genetics; D013816:Thermodynamics; D059004:Topoisomerase I Inhibitors
chemical_list: D004791:Enzyme Inhibitors; D009692:Nucleic Acid Heteroduplexes; D059004:Topoisomerase I Inhibitors; C066731:10,11-methylenedioxy-20-camptothecin; D000077146:Irinotecan; D004247:DNA; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin